CHMP recommends two dose Cervarix Cervical Cancer vaccine
GSK has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) is recommending marketing authorisation for a two-dose schedule in 9-14 year old girls for its cervical cancer vaccine, Cervarix [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] in young adults with high coverage. A two-dose vaccine schedule has the potential to be easier to deliver than a three-dose schedule, thereby expanding the population that could benefit from protection.
The EU licence application is based on the results of a Phase III study (HPV-070) which showed that two doses of the vaccine in girls aged nine to fourteen years provide an immunogenicity matching the currently licensed three-dose schedule in fifteen to twenty five year olds.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.